Corrigendum to “Pseudogene CYP4Z2P 3′UTR promotes angiogenesis in breast cancer.” [Biochem. Biophys. Res. Commun. 2014 oct 24, 453(3), 545–51](S0006291X14017495)(10.1016/j.bbrc.2014.09.112);Pseudogene CYP4Z2P 3′UTR promotes angiogenesis in breast cancer

Biochemical and Biophysical Research Communications

Volumn 453, Issue 3, 2014, Pages 545-551

  Zheng, Lufeng ^a   Li, Xiaoman ^a   Gu, Yi ^a   Ma, Yihua ^a   Xi, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

3 UTR; Angiogenesis; Breast cancer; CYP4Z2P; VEGF A

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; 3' UNTRANSLATED REGION; CYTOCHROME P450; MESSENGER RNA; PRIMER DNA;

3' UNTRANSLATED REGION; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PARACRINE SIGNALING; PSEUDOGENE; PSEUDOGENE CYP4Z2P 3' UNTRANSLATED REGION; ANIMAL; BREAST TUMOR; CELL LINE; CHEMISTRY; CHICK EMBRYO; CONFORMATION; FEMALE; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULARIZATION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CHICK EMBRYO; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEIC ACID CONFORMATION; PSEUDOGENES; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84918575173     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2019.10.131     Document Type: Erratum

References (29)

1. R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, CA Cancer J. Clin. 63 (2013) 11-30.
2. R.S. Alameddine, Z.K. Otrock, A. Awada, A. Shamseddine, Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges, Curr. Opin. Oncol. 25 (2013) 313-324.
3. J. Welti, S. Loges, S. Dimmeler, P. Carmeliet, Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer, J. Clin. Invest. 123 (2013) 3190-3200.
4. R.R. Somani, U.V. Bhanushali, Targeting angiogenesis for treatment of human cancer, Indian J. Pharm. Sci. 75 (2013) 3-10.
5. F. Zagouri et al., Serum MMPs and TIMPs: may be predictors of breast carcinogenesis?, Clin Chim. Acta 412 (2011) 537-540.
6. K.M. Cook, W.D. Figg, Angiogenesis inhibitors: current strategies and future prospects, CA Cancer J. Clin. 60 (2010) 222-243.
7. D. Torrents, M. Suyama, E. Zdobnov, P. Bork, A genome-wide survey of human pseudogenes, Genome Res. 13 (2003) 2559-2567.
8. M. Clamp et al., Distinguishing protein-coding and noncoding genes in the human genome, Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 19428-19433.
9. S. Zhao et al., Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma, J. Pathol. 223 (2011) 672-682 (7.76).
10. O.H. Tam et al., Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes, Nature 453 (2008) 534-538.
11. Y. Tay et al., Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs, Cell 147 (2011) 344-357.
12. M.A. Rieger, Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma, Cancer Res. 64 (2004) 2357-2364.
13. M. Cesana, D. Cacchiarelli, I. Legnini, T. Santini, O. Sthandier, M. Chinappi, A. Tramontano, I. Bozzoni, A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA, Cell 147 (2011) 358-369.
14. M.S. Kumar, E. Armenteros-Monterroso, P. East, P. Chakravorty, N. Matthews, M.M. Winslow, J. Downward, HMGA2 functions as a competing endogenous RNA to promote lung cancer progression, Nature 505 (2014) 212-217.
15. S.H. Oh et al., Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma, Clin. Cancer Res. 12 (2006) 653-661.
16. T. Yi et al., Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways, Mol. Cancer Ther. 7 (2008) 1789-1796.
17. W. Yu et al., Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer, Toxicol. Appl. Pharmacol. 264 (2012) 73-83.
18. D.Y. Lee, A 3′-untranslated region (3′UTR) induces organ adhesion by regulating miR-199a∗ functions, PLoS One. 4 (2010) e4527.
19. K. Sossey-Alaoui et al., Kindlin-3 enhances breast cancer progression and metastasis by activating twist-mediated angiogenesis, FASEB J. 28 (2014) 2260-2271.
20. S. Ziyad, M.L. Iruela-Arispe, Molecular mechanisms of tumor angiogenesis, Genes Cancer 2 (2011) 1085-1096.
21. L. Li, D. Wang, M. Xue, X. Mi, Y. Liang, P. Wang, 3′UTR shortening identifies high-risk cancers with targeted dysregulation of the ceRNA network, Sci. Rep. 4 (2014) 5406.
22. J. Jia, P. Yao, A. Arif, P.L. Fox, Regulation and dysregulation of 3′UTR-mediated translational control, Curr. Opin. Genet. Dev. 23 (2013) 29-34.
23. L.E. Skeeles, J.L. Fleming, K.L. Mahler, A.E. Toland, The impact of 3′UTR variants on differential expression of candidate cancer susceptibility genes, PLoS One 8 (2013) e58609.
24. L. Salmena, L. Poliseno, Y. Tay, L. Kats, P.P. Pandolfi, A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?, Cell 146 (2011) 353-358
25. C. Mayr, D.P. Bartel, Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells, Cell 138 (2009) 673-684.
26. M.D. Muhlebach et al., Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus, Cancer Res. 70 (2010) 7620-7629.
27. M. Barylski, E. Kowalczyk, L. Pawlicki, R. Irzmanski, A. Mejer, I. Szadkowska, J. Kowalski, Tissue inhibitor of metalloproteinases-1 level in patients with metabolic syndrome qualified for cardiac rehabilitation, Pol. Merkuriusz Lek. 30 (2011) 246-248.
28. M. Los, J.M. Roodhart, E.E. Voest, Target practice. Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer, Oncologist 12 (2007) 443-450.
29. , 2014.